MedTrace Logo

Post-Market Study to Assess iTind Safety in Comparison to UroLift

NCT04757116 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 206

Last updated 2026-05-06

No results posted yet for this study

Summary

The study objective is to evaluate the safety of the iTind device comparied to UroLift.

Conditions

  • Benign Prostatic Hyperplasia (BPH)

Interventions

DEVICE

iTind

The iTind is implemented for 5-7 days

PROCEDURE

UroLift

UroLift is a minimally invasive procedure where permanent implants are placed in the prostate.

Sponsors & Collaborators

  • Olympus Europe SE & Co. KG

    collaborator INDUSTRY

  • Olympus Corporation of the Americas

    lead INDUSTRY

Principal Investigators

  • Bilal Chughtai, MD · Northwell Health

  • Neil Barber, MD · Frimley Park Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-26
Primary Completion
2026-06-30
Completion
2031-12-31
FDA Device
Yes

Countries

  • United States
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04757116 on ClinicalTrials.gov